Where can I buy shares of bio?
Find the latest Bio-Rad Laboratories, Inc. (BIO-B) stock quote, history, news and other vital information to help you with your stock trading and investing.
Is Bio-Rad Laboratories (BIO) stock up 0% in one week?
Mar 29, 2022 · View BioRad Laboratories, Inc BIO.B investment & stock information. Get the latest BioRad Laboratories, Inc BIO.B detailed stock quotes, stock …
How much of Translate Bio's stock is owned by institutions?
Bio-Rad Laboratories, Inc. Class B Common Stock (BIO.B) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Should you hold Translate Bio (TBIO) stock?
BIO: Lowering target price to $629.00BIO-RAD LABORATORIES-A has an Investment Rating of BUY; a target price of $629.000000; an Industry Subrating of High; a …
BioRad Laboratories, Inc. (BIO.B)
Zacks' 7 Best Strong Buys for September, 2021
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Can Retail Earnings Hold Up in the Face of the Delta Variant?
Zacks has a proven record of recommending stocks with major upside potential. This report reveals 7 stocks predicted to have explosive gains over the next 30-90 days. A recent pick, Fiverr, spiked +84.6% in just 30 days. In today's bull market, these stocks could climb even higher. See our 7 Best Stocks absolutely FREE.
Bull of the Day
Earnings from traditional brick-and-mortar retailers have been strong in the Q2 reporting cycle. Can they continue amid the context of rising Delta-variant infection rates?
Bear of the Day
The exchange that oversees trading in most tech and bio tech stocks is a stock itself!
ETFs
Estimates have dropped and that has pushed this stock to the lowest Zacks Rank.
Mutual Funds
Disney's impressive third-quarter fiscal 2021 earnings results might be a positive for the ETFs, especially those that have the...
Cooper Companies (COO) Q3 Earnings & Revenues Beat Estimates
The surge in coronavirus cases due to the delta virus variant and Taliban's taking control of Afghanistan may cause...
Patterson Companies (PDCO) Q1 Earnings & Revenues Top Estimates
Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.
What Makes Bio-Rad (BIO) a Good Fit for "Trend Investing"
Patterson Companies' (PDCO) fiscal first-quarter 2022 results benefit from strong segmental performance.
Bio-Rad to Participate in the 2021 Virtual Wells Fargo Healthcare Conference
Bio-Rad (BIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Catalent's (CTLT) Q4 Earnings Top Estimates, Margins Rise
HERCULES, Calif., August 31, 2021--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that management will participate in a Fireside Chat at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, at 11:40 AM (Pacific Time).
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
Catalent's (CTLT) robust performance across the majority of its segments drives its fourth-quarter fiscal 2021 top line.
What's in Store for Patterson Companies' (PDCO) Q1 Earnings?
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Is Bio-Rad Laboratories a buy right now?
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect improvement at Dental segment.
What stocks does MarketBeat like better than Bio-Rad Laboratories?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last twelve months. There are currently 3 buy ratings for the stock.
When is Bio-Rad Laboratories' next earnings date?
Wall Street analysts have given Bio-Rad Laboratories a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bio-Rad Laboratories wasn't one of them.
How were Bio-Rad Laboratories' earnings last quarter?
Bio-Rad Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.#N#View our earnings forecast for Bio-Rad Laboratories.
How has Bio-Rad Laboratories' stock price been impacted by COVID-19?
Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its earnings results on Wednesday, July, 28th. The medical research company reported $3.54 earnings per share for the quarter, beating the consensus estimate of $2.66 by $0.88. The medical research company had revenue of $715.93 million for the quarter, compared to analyst estimates of $610.40 million.
What guidance has Bio-Rad Laboratories issued on next quarter's earnings?
Bio-Rad Laboratories' stock was trading at $345.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BIO stock has increased by 137.2% and is now trading at $820.10.#N#View which stocks have been most impacted by COVID-19.
What price target have analysts set for BIO?
Bio-Rad Laboratories issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.77 billion-$2.78 billion, compared to the consensus revenue estimate of $2.71 billion.
